News
That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...
U.S. companies are increasingly issuing bonds in the euro credit market as it is cheaper than issuing in the dollar credit market, CreditSights said. "A mix of European Central Bank policy loosening ...
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...
HONG KONG (AP) — Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...
"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...
U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results